GLP Global Partners LP

Mentions (48)

• Newscnbc.com·3d ago·Neutral

  Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs.  A new slate of injections, pills, and combination regimens target the amylin pathway, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness.

  View source ↗
• Newsglobenewswire.com·4d ago·Negative

  Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment  A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of …

  View source ↗
• Newsprnewswire.com·5d ago·Negative

  Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare syst…

  View source ↗
• Newsprnewswire.com·5d ago·Neutral

  Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. in…

  View source ↗
• Newsproactiveinvestors.com·7d ago·Negative

  Solvonis says alcohol treatment outpaces GLP-1 drugs in cross-trial comparison Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) says new analysis of its ketamine-based alcohol treatment shows patients cut heavy drinking days by 67% compared with placebo, more than four months after their last dose. The company says that puts SVN-001 ahead of naltrexone, sold as Vivitrol, and the GLP-1 drugs semaglutide and pemvidutide on the same measure.

  View source ↗
• Newscnbc.com·11d ago·Neutral

  Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company's position in the market – including in the burgeoning obesity pill space.

  View source ↗
• Newsfool.com·11d ago·Negative

  Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate.

  View source ↗
• Newsetftrends.com·12d ago·Negative

  NTHM ETF Rotates Into Midstream Energy & GLP-1 Healthcare The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss drug manufacturers. The fund tracks the Thematic Rotation Quality Momentum Screened Index (TRQMS).

  View source ↗
• Newszacks.com·12d ago·Positive

  Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.

  View source ↗
• Newsproactiveinvestors.com·14d ago·Negative

  GLP-1 maker Novo Nordisk's big reveal leaves the City cold Novo Nordisk (NYSE:NVO) pulled back the curtain on its future at an investor day in London, and the audience filed out distinctly underwhelmed. The Danish drugs giant, best known for the weight-loss sensation Wegovy, used its biennial capital markets day to explain how it will thrive once its blockbuster obesity drugs lose patent protection.

  View source ↗
• Newsprnewswire.com·14d ago·Negative

  Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens 22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to Treatment Up to 97% of Weight Loss Maintained Following Transition…

  View source ↗
• Newscnbc.com·14d ago·Negative

  Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July. In an exclusive interview, Ricks said 70% of those patients are on Lilly medicines.

  View source ↗
• Newscnbc.com·14d ago·Negative

  Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

  View source ↗
• Newsmarketbeat.com·15d ago·Neutral

  WW International Eyes Cash Flow Turnaround as GLP-1 Care Gains Momentum WW International NASDAQ: WW executives outlined the company's efforts to reposition its weight-management business around behavioral support, telehealth and GLP-1 medications, following a restructuring that substantially reduced its debt burden.

  View source ↗
• Newsyoutube.com·17d ago·Positive

  40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania" Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated through earnings and weighs if Novo (NVO) has a chance to catch up.

  View source ↗
• Newsseekingalpha.com·18d ago·Negative

  Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m ca…

  View source ↗
• Newsaccessnewswire.com·21d ago·Neutral

  The GLP-1 Era Has a Trust Problem - AimwellBio is Building the Physician Network to Solve It Company plans to integrate telemedicine into its verified health intelligence platform and opens a ten-seat Founding Physician Cohort spanning GLP-1 and metabolic care, hormone and menopause health, and physician-directed therapies for men and women. MIAMI, FL / ACCESS Newswire / September 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today announced plans to integrate tele…

  View source ↗
• Newsyoutube.com·24d ago·Neutral

  Making Getting Skinny Taste Good: Cava CEO On The GLP-1 Boom From smaller portions and adults ordering kids meals to more protein and Mediterranean-style eating, Cava CEO Brett Schulman breaks down how GLP-1s are changing customer behavior. Check out our daily newsletter!

  View source ↗
• Newszacks.com·24d ago·Neutral

  Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.

  View source ↗
• Newsbenzinga.com·26d ago·Positive

  Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.

  View source ↗
• Newsglobenewswire.com·27d ago·Negative

  Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada's GLP-1 Program SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada's GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease r…

  View source ↗
• Newszacks.com·33d ago·Neutral

  3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP) Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

  View source ↗
• Newsmarketbeat.com·33d ago·Neutral

  Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity Eli Lilly and Company TodayLLYEli Lilly and Company$1,171.40 +11.40 (+0.98%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$712.05▼$1,292.65Dividend Yield0.59%P/E Ratio39.28Price Target$1,292.18Add to WatchlistOn Aug. 31, Eli Lilly & Co. NYSE: LLY announced its intention to acquire Merida Biosciences for $2.875 billion.

  View source ↗
• Newsproactiveinvestors.co.uk·33d ago·Positive

  Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell' Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 Danish krone against a last close of 292.4 Danish krone. Analyst Emmanuel Papadakis published Citi's weekly IQVIA tracker of Novo's GLP-1 assets, using retail prescription data up to 21 August 2026.

  View source ↗
• Newsmarketbeat.com·34d ago·Negative

  Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.

  View source ↗
• Newsfool.com·35d ago·Neutral

  Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.

  View source ↗
• News247wallst.com·35d ago·Negative

  Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.

  View source ↗
• Newsreuters.com·35d ago·Negative

  GLP-1 weight loss drugs effective even at low starter doses People taking popular GLP-1 obesity drugs who remain on low starter doses will ​lose some weight but may still experience side effects, although significantly less nausea than those who graduate ‌to higher manufacturer-recommended doses, a new study suggests.

  View source ↗
• Newsreuters.com·35d ago·Negative

  Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as ​it continues to expand its international business.

  View source ↗
• Newsfool.com·36d ago·Negative

  Should Eli Lilly Investors Be Worried About a Threat From Amylyx? Eli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026. Amylyx is one of many competitors seeing success in developing new GLP-1 drugs.

  View source ↗
• News247wallst.com·38d ago·Negative

  GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall? Employer insurance coverage for GLP-1 weight-loss drugs is shrinking, yet Eli Lilly just posted a 47% revenue surge. Something underneath the headlines is keeping volumes alive, and it changes how shareholders should read every coverage headline going forward.

  View source ↗
• Newsbarrons.com·39d ago·Negative

  Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.

  View source ↗
• Newsbusinesswire.com·42d ago·Neutral

  IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers NEW DELHI--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF's GLP-1 global consumer insights following the company's 2025 GLP-1 Consumer Opportu…

  View source ↗
• Newsproactiveinvestors.co.uk·43d ago·Neutral

  Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifies Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to the injections that have dominated the market. Foundayo, also known as orforglipron, is available on private prescription after the Medicines and Healthcare products Regulatory Agency approved it earlier this month.

  View source ↗
• Newsseekingalpha.com·45d ago·Neutral

  Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030 Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value infle…

  View source ↗
• Newsfool.com·46d ago·Neutral

  There's a Black Market for Eli Lilly's Unapproved GLP-1 Drug. Here's Why That's Bullish Eli Lilly's unapproved retatrutide is already popular, as evidenced by the black market for it. This underscores the strength of Eli Lilly's weight-loss pipeline.

  View source ↗
• Newszacks.com·46d ago·Negative

  Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.

  View source ↗
• Newsglobenewswire.com·47d ago·Positive

  Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Da…

  View source ↗
• Newsinvezz.com·48d ago·Negative

  Amylyx stock soars on GLP-1 success: here's why investors should sell Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).

  View source ↗
• Newsbarrons.com·49d ago·Negative

  Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.

  View source ↗
• Newszacks.com·49d ago·Neutral

  Is Global Partners (GLP) a Solid Growth Stock? 3 Reasons to Think "Yes" Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

  View source ↗
• Newsfool.com·52d ago·Neutral

  GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline.

  View source ↗
• Newszacks.com·53d ago·Neutral

  Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.

  View source ↗
• Newsglobenewswire.com·55d ago·Negative

  Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission Final histology and laboratory analyses support the study's safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP)

  View source ↗
• Newsmarketbeat.com·55d ago·Negative

  Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring Apyx Medical NASDAQ: APYX is positioning its Renuvion technology and newly launched AYON Body Contouring System to address growing demand for surgical aesthetic procedures, a trend CEO Charlie Goodwin said has been reshaped by the increasing use of GLP-1 weight-loss drugs.

  View source ↗
• Newsmarketbeat.com·56d ago·Neutral

  Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.

  View source ↗
• Newszacks.com·56d ago·Positive

  GLP Q2 Earnings Call Flags Hedging Costs Amid Strong Fuel Margins Global Partners flags higher hedged-inventory carrying costs from steep backwardation, even as strong fuel margins lifted second-quarter product margins.

  View source ↗
• Newsfool.com·58d ago·Positive

  Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

  View source ↗